World Health Organization, South-East Asia Regional Office
South-East Asia Region
Expanded Programme on Immunization (EPI)
REGIONAL FACT SHEET 2017
WHO South-East Asia Region
Acronyms
AD
Auto disable
MCV1
First dose MCV
AEFI
Adverse events following immunization
MCV2
Second dose MCV
AFP
Acute flaccid paralysis
MICS
Multiple indicator cluster survey
BCG
Bacillus Calmette-Guérin vaccine
MMR
Measles mumps rubella vaccine
CES
Coverage evaluation survey
MNT
Maternal and neonatal tetanus
cMYP
Comprehensive multi-year plan
MR
Measles rubella vaccine
CRS
Congenital rubella syndrome
NCIP
National committee on immunization practices
DHS
Demographic health survey
NID
National immunization day
DT
Diphtheria tetanus toxoid, pediatric
NTAGI
National technical advisory group on immunization
DTP
Diphtheria – tetanus – pertussis vaccine
NT
Neonatal tetanus
DTP3
3rd dose DTP
OPV
Oral poliovirus vaccine
DTP-Hib-HepB
Pentavalent vaccine
OPV3
3rd dose OPV
DTP-Hib-HepB3
3rd dose pentavalent vaccine
bOPV
Bivalent OPV
EPI
Expanded Programme on Immunization
tOPV
Trivalent OPV
GDP
Gross domestic product
PCV
Pneumococcal conjugate vaccine
HCW
Health care worker
SEAR
WHO South-East Asia Region
HepB
Hepatitis B vaccine
SEARO
WHO South-East Asia Regional Office
HepB3
3rd dose HepB
SIA
Supplementary immunization activities
Hib
Haemophilus influenzae type B vaccine
SNID
Subnational immunization day
HPV
Human papilloma virus vaccine
Td
Tetanus diphtheria toxoid; older children, adults
IgM
Immunoglobulin M
TT
Tetanus toxoid
IPV
Inactivated poliovirus vaccine
TT2+
2 or more doses TT
JE
Japanese encephalitis
VDPV
Vaccine derived poliovirus
JE_Live-Atd
JE live attenuated vaccine
VPD
Vaccine preventable diseases
JRF
WHO UNICEF Joint Reporting Form
WCBA
Women of child bearing age
LB
Live birth
WPV
Wild poliovirus
M
Measles
Contents
Page
No.
Maternal and neonatal tetanus elimina�on is sustained
WHO South-East Asia Region
Page
No.
Regional demographic atributes
SEAR populaion density by irst administraive level
Figure 1
5
Basic informaion, 2016
Table 1
6
Page
No.
Rou�ne immuniza�on systems and services
TT2+ coverage by country, 2012-2016
Figure 9
13
MNT eliminaion status
Figure 10
13
Page
No.
Polio-free status is maintained
NID/SNID and date of last WPV conirmed cases, 1995-2016 by country
Table 7
14
Last WPV conirmed cases by type in SEAR
Figure 11
14
Table 8
14
Rouine immunizaion schedules by country, 2016
Table 2
7
Environmental surveillance for poliovirus detecion, 2014-2016
BCG, DPT3, OPV3, MCV1, MCV2, HepB 3 and RCV coverage in SEAR, 2000-2016
Figure 2
8
AFP surveillance indicators by country, 2014-2016
Table 9
15
Rouine immunizaion coverage esimates, 2012-2016
Table 3
9
AFP surveillance indicators by irst administraive level, 2016
Figure 12
15
Planning and management indicators, 2016
Table 4
10
Vaccine safety, 2016
Table 5
10
Towards measles elimina�on and rubella/congenital rubella
syndrome control
Reported vaccine preventable diseases, 2014-2016
Table 6
11
DTP3 coverage by country, 2012-2016
Figure 3
12
Districts achieving >80% DTP3 coverage by country, 2012-2016
Figure 4
DTP1-DTP3 drop-out by country, 2012-2016
DTP3 immunizaion coverage by irst administraive level, 2016
Page
No.
MCV1 coverage by country, 2012-2016
Figure 13
16
12
Status of sub-naional coverage for 1st dose of measles and
rubella containing vaccine in the SEA Region, 2016
Figure 14
16
Figure 5
12
Rubella vaccine introducion through rouine immunizaion
Figure 15
16
Figure 6
12
Suspected measles cases and outbreaks by country, 2016
Table 10
17
Measles and rubella laboratory surveillance indicators, 2016
Table 11
18
Network of WHO supported laboratories for VPD surveillance in SEAR
Figure 16
19
Page
No.
Control of Hepa��s B is accelerated
HepB3 coverage, 2012-2016
Figure 7
13
HepB vaccine use
Figure 8
13
The Immunizaion and Vaccine Development (IVD) unit of the Department of Family Health, Gender and Life Course (FGL), World Health Organizaion (WHO), Regional Oice
for South-East Asia (SEARO) has been producing annually the Expanded Programme on Immunizaion (EPI) fact sheets since 2002 for all SEA countries and the region. The
primary data source of the EPI fact sheets are the WHO-UNICEF joint reporing form (JRF) and SEARO annual EPI reporing form (AERF) in which each country oicially reports
EPI and vaccine preventable diseases (VPD) related core informaion annually. The EPI factsheets 2017 are based on 2016 data reported to WHO SEARO by the Member States.
Regional demographic attributes
Figure 1: SEAR population density by first administrative level*
*Populaion density by second administraion
level for Bhutan, Sri Lanka and Timor-Leste.
Disclaimer: The boundaries and names shown and the designaions used on all the maps do not
imply the expression of any opinion whatsoever on the part of the World Health Organizaion
concerning the legal status of any country, territory, city or area of its authoriies, or concerning the
delimitaion of its froniers or boundaries.
5
Table 1: Basic information, 2016
2016 popula�on1
Mortality2
Administra�ve levels1
Live births
Children
< 1 year
Children
< 5 years
Children
< 15 years
Neonatal
mortality rate
(per 1000 LB)
Infant
mortality rate
(per 1000 LB)
Under ive
mortality rate
(per 1000 LB)
Maternal
mortality
ra�o (per
100000 LB)
Number of
provinces /
regions /
divisions
Number
of
districts
160,707,634
3,279,741
3,138,712
15,507,183
50,339,679
23.3
30.7
37.6
176
8
64
Bhutan
757,042
12,869
11,227
82,561
229,796
18.3
27.2
32.9
148
-
20
DPR Korea
24,327,698
342,884
339,367
1,696,094
5,927,740
13.5
19.7
24.9
82
11
210
India
1,300,000,000
27,005,535
26,008,988
121,400,000
400,700,000
27.7
37.9
47.7
174
36
676
Indonesia
258,704,986
4,858,600
4,760,891
23,960,310
70,096,861
13.5
22.8
27.2
126
34
514a
Maldives
338,434
6,592
8,711
16,311
91,793
4.9
7.4
8.6
68
-
20
Myanmar
52,088,703
1,009,793
945,877
4,626,063
14,493,639
26.4
39.5
50
178
17
330b
Nepal
28,624,299
637,263
660,629
2,959,177
8,676,336
22.2
29.4
35.8
258
5
75
Sri Lanka
21,164,458
331,073
330,461
1,820,143
5,333,443
5.4
8.4
9.8
30.0
9
26
Thailand
65,931,550
704,058
627,185
3,565,020
11,433,331
6.7
10.5
12.3
20
77
928
TimorLeste
1,231,262
35,426
33,548
176,377
493,795
22.3
44.7
52.6
215
-
13
SEAR
1,913,876,066
38,223,834
36,865,596
175,809,239
567,816,413
24.3
34
42.5
164
-
-
Country
Total
popula�on
Bangladesh
Source:
1
SEAR annual EPI reporing form, 2016
2
WHO, World Health Staisics ,2016
a
District & city
6
b
Township
Routine immunization systems and services
Table 2: Routine immunization schedules by country, 2016
Country
BCG
DTP
HepB
MCV
OPV
Other vaccina�ons
TT
Vitamin A
6-59M
(not given
through EPI)
PCV- 6W, 10W, 18W
Bangladesh
At birth
DTPHibHepB - 6W, 10W, 14W
MR-38W, 15M
6W, 10W, 14W
IPV-14W
Females 15Y to 49Y (5 doses with an
interval of + 1 month, + 6 months, + 1 year
and + 1 year with preceding dose)
Bhutan
At birth
HepB- At birth
DTPHibHepB- 6W, 10W, 14W
DTP- 24M
MMR- 9M, 24M
At birth, 6W, 10W, 14W
IPV-14W
Td- 6Y, 12Y
6-30M
HPV- Girls 12Y & Grade VI students
DPR Korea
At birth
HepB- At birth
DTPHibHepB - 6W, 10W, 14W
Measles-9M,
15M
6W, 10W, 14W
IPV-14W
Td - 3M, 4M of pregnancy
6-59M
-
India
At birth
HepB - At birth
DTPHibHepB - 6W, 10W, 14W
DTP - 16-24M, 5Y
Measles-9-12M,
16-24M
MR- 9M-2Y
(Feb 2017,
subnaional)
At birth, 6W, 10W, 14W,
16-24M
IPV- 6W, 14W (as fracional
dose)
10Y and 16Y, 2 doses/booster for pregnant
women
9 months, 18
months and
6 months
interval ill
age 5 years
JE_LiveAtd - 9M and 16-24M (JE endemic
districts)
PCV - (Apr 2017, upto 1Y, subnaional)
Rotavirus-6W,10W,14W (…..2017, upto
1 year, subnaional)
Indonesia
1M
HepB- 0-7 days of birth
DTPHibHepB - 2M, 3M, 4M, 18M
Measles-9M,
24 M
1M, 2M, 3M, 4M
IPV-4M
TT- 15-39Y female
DT - 6-7Y
Td- 7-8Y , 8-9Y
6-59M
-
Maldives
At birth
HepB-At birth
DTPHibHepB - 2M, 4M, 6M
Measles-9M
MMR - 18M
2M, 4M, 6M (+15Y pilgrims)
IPV-6M
Td - Females 15Y (+1M, +6M, +1Y, +1Y)
9-59M
Men ACWY- +15Y pilgrims
YF- +15Y travelers
Myanmar
Birth to 2M
HepB- At birth
DTPHibHepB- 2M, 4M, 6M
MR- 9M
Measles- 18M
2M, 4M, 6M
IPV- 4M
First contact during pregnancy and 4 weeks
later
6-59M
-
Nepal
At birth
DTPHibHepB - 6W, 10W, 14W
MR-9M, 15M
6W, 10W, 14W
IPV-14W
Td- First contact pregnancy, +1M
6-59M, +6M
JE_LiveAtd - 12M (high-risk districts)
PCV- 6W, 10W, 9M
MMR - 9M, 3Y
2M, 4M, 6M, 18M, 5Y
IPV- 2M, 4M (as fracional
dose)
DT - 5Y
Td - 12Y (grade 7)
TT - Pregnant women (2 doses in 1st
pregnancy and 1 dose in subsequent 3
pregnancies)
6-36M
JE_LivteAtd - 1Y
Typhoid - high risk groups
At birth
DTPHibHepB - 2M, 4M, 6M
DTP - 18M
Thailand
At birth
HepB - At birth, 1M (new-born
from HepB carrier mother)
DTPHepB - 2M, 4M, 6M
DTP - 1.5Y, 4Y
Timor-Leste
At Birth
HepB- At birth (Feb 2016)
DTPHibHepBIPV- 6W, 10W, 14W
DPT-18M
Sri Lanka
Source: WHO/UNICEF JRF 2016
MMR - 9M, 2.5Y
2M, 4M, 6M, 1.5Y, 4Y
IPV-4M
Td- 12Y (grade 6), Pregnant women
1st contact, +1M, +6M (depending on
vaccinaion history)
-
JE_LiveAtd- 1.5Y, 2.5Y (29 provinces)
JE_Inactd - 1.5Y (2 doses 1M apart), 2.5Y
Rotavirus- 2m, 4M (pilot in selected
provinces)
HPV- females at grade 5 and grade 6
(pilot in selected provinces)
MR-9M, 18 M
Birth, 6W, 10W, 14W
IPV-14W
Females 15Y-49Y (1st pregnancy contact,
+1M, +6M, +1Y, +1Y)
DT- 6Y
6-36M (6M
interval)
-
W=Week
M=Month
7
Y=Year
Figure 2: BCG, DPT3, OPV3, MCV1, MCV2, HepB 3 and RCV coverage in SEAR, 2000-2016
100
80
Coverage (%)
60
40
20
Year
BCG
DPT3
OPV3
MCV1
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
8
MCV2
HepB3
RCV
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
0
Table 3: Routine immunization coverage estimates, 2012-2016
BCG
Country
DTP3
OPV3
MCV1
2012
2013
2014
2015
2016
2012
2013
2014
2015
2016
2012
2013
2014
2015
2016
2012
2013
2014
2015
2016
Bangladesh
98
99
99
99
99
94
96
97
97
97
94
96
97
97
97
88
91
94
94
94
Bhutan
95
97
99
99
99
97
97
99
99
98
97
97
98
98
97
95
94
97
97
97
DPR Korea
98
98
98
97
97
96
93
93
96
96
99
99
99
99
99
99
99
99
98
99
India
90
91
89
87
89
82
83
85
87
88
79
82
84
86
86
83
83
85
87
88
Indonesia
88
86
82
80
81
83
85
78
78
79
84
86
80
80
80
82
81
75
75
76
Maldives
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
98
99
99
99
99
Myanmar
87
86
92
94
88
84
75
88
89
90
87
76
88
89
89
84
86
88
84
91
Nepal
96
97
99
94
93
90
92
92
91
87
90
92
92
90
85
86
88
88
85
83
Sri Lanka
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
Thailand
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
98
99
99
99
99
Timor-Leste
86
86
84
84
85
83
82
77
76
85
83
82
76
75
83
73
70
74
70
78
SEAR
91
91
90
88
89
84
85
86
87
88
82
84
85
87
87
84
84
85
86
87
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
9
Most recent EPI CES
India
Updated microplans that include
ac�vi�es to improve
immuniza�on
coverage
DPR Korea
Spending on rou�ne
immuniza�on
programme by the
government
Bhutan
Table 5: Vaccine safety, 2016
Spending on vaccines
by the government
Bangladesh
NTAGI
Country
cMYP for
immuniza�on
Table 4: Planning and management indicators, 2016
27%
29%
64 districts
(100%)
EPI CES 2015
24%
20 districts
(100%)
Naional Health Survey,
2012
no data
210 districts
(100%)
CES and MICS
56%
676 districts
(100%)
Naional Family Health
Survey-4 2015
Indonesia
Yes
11,832
112
Maldives
Yes
2
0
2014-2018
fully
funcional
2014-2018
fully
funcional
41%
2016-2020
fully
funcional
no
data
2013-2017
fully
funcional
50%
Adverse events following immuniza�on (AEFI)
Country
Na�onal system
to monitor AEFI
No. AEFI
Reported
Of the total adverse
events reported no. of
serious
Bangladesh
Yes
2,563
54
Bhutan
Yes
ND
9
DPR Korea
Yes
-
-
India
Yes
1,393
1280
Indonesia
2015-2019
fully
funcional
90%
88%
ND
Basic Health Survey 2013,
District Coverage Survey
in 10 provinces and 31
districts 2015
Maldives
2016-2020
fully
funcional
100%
72%
20 atolls
(100%)
DHS ongoing
Myanmar
Yes
63
10
Myanmar
2017 -2021
fully
funcional
6%
24%
ND
Demographic and Health
Survey 2015-2016
Nepal
Yes
1,684
34
Nepal
2011-2016
fully
funcional
22%
24%
75 districts
(100%)
Demographic Health
Survey 2016
Sri Lanka1
Yes
9,389
225
Sri Lanka
2017-2021
fully
funcional
no
data
74%
26 districts
(100%)
EPI coverage survey
Nuwara Eliya district 2016
Thailand
Yes
751
0
Thailand
2012-2016
fully
funcional
no
data
no data
77 provinces
(100%)
CES for basic and schoolbased immunizaion 2013
Timor-Leste
Yes
ND
0
Timor-Leste 2016-2020
fully
funcional
39%
13 districts
(100%)
EPI CES Dili municipality
and 12 other
municipaliies 2015
Source: WHO/UNICEF JRF, 2016
76%
ND: no data
10
Source: WHO/UNICEF JRF, 2016
Adverse Events Following Immunizaion; Sri Lanka AEFI data do not relect cases
but events.
1
Table 6: Reported vaccine preventable diseases, 2014-2016
Pertussis
Total
tetanus (NT)
Measles
Rubella
Mumps
JE
Polio
Diphtheria
Pertussis
Total
tetanus (NT)
Measles
Rubella
Mumps
JE
Polio
Diphtheria
Pertussis
Total
tetanus (NT)
Measles
Rubella
Mumps
JE
2016
Diphtheria
2015
Polio
2014
Bangladesh
0
13
12
ND
289
381
ND
183
0
6
11
559
(117)
240
189
ND
76
0
2
1
441
(110)
972
165
ND
1,294
Bhutan
0
0
0
0
0
0
206
2
0
0
12
0
11
1
620
5
0
0
4
0
45
3
795
5
DPR Korea
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
India
0a 6,094 46,706
5,017
26,530
(492)
5,716
0
Indonesia
0
430
2,082
1,023
12,943
(75)
3,542
ND
72
0
252
1,004
ND
(69)
9,863
826
ND
39
0
342
Maldives
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
Myanmar
0
29
5
73
(32)
122
30
ND
50
0c
87
5
ND
(30)
6
34
ND
113
Nepal
0 1,079
6,096
ND
(57)
1,279
704
34,034 1,304 0
236
4,416
888
(266)
1,599
626
38,858
Sri Lanka
0
0
38
9 (0)
1,686
10
383
21
0
0
107
15 (0)
1,568
9
Thailand
0
19
14
81 (2)
146
152
3,704
31
0
19
51
0
154
Timor-Leste 0
2
0
0
47
1
0
0
0
1
5
0
48
Country
SEAR
a
0 7,666 54,953
Excludes 3 VPDVs (type 2)
b
1,657 0b 2,365 25,206
3,781
(227)
17,250 10,311
ND
1,627
826
33(6%)
6,962
1,238
ND
43
0
0
0
0
0
0
0
0
136
2
194
(21)
266
10
ND
393
937
0
140
4,890
766 (7)
1,269
656
30,610
98
ND
17
0
0
54
5(0)
112
0
311
18
240
3,121
23
0
16
84
61 (0)
652
7
23
21
5
ND
0
0
0
6
0
2
8
0
1
2,268
30,168 5,850
(491)
ND
1,620 0d 3,380 37,274
6,126
3,730
43,045 10,536 38,327 3,320 0 2,966 30,817
43,657 7,783 42,599 2,830 0 4,016 43,141
(658)
(933)
Excludes 2 VDPVs (type 2)
c
Excludes 2 cVDPVs (type 2)
d
Excludes 1 VDPV (Type 2)
Source: WHO/UNICEF JRF (2014-2016)
ND=No data
11
5,250
(366)
27,530 12,398 31,739 3,500
Figure 4: Districts achieving >80% DTP3 coverage
Figure 3: DTP3 coverage by country, 2012-2016
by country, 2012-2016
100
100
80
2012
80
2012
2013
60
60
2013
2014
40
2014
2015
40
2015
2016
20
20
2016
0
0
Bangladesh
Bangladesh
Bhutan
DPR Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Bhutan
DPR Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Timor-Leste
Source: WHO/UNICEF JRF , 2017
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
Figure 5: DTP1-DTP3 drop-out by country, 2012-2016
* data from province level
Figure 6: DTP3 immunization coverage by
first administrative level*, 2016
20
15
2012
2013
10
2014
2015
5
Timor-Leste
Thailand
Sri Lanka
Nepal
Myanmar
Maldives
Indonesia
India
DPR Korea
Bhutan
0
Bangladesh
2016
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
*Thailand, Bhutan, Maldives & Timor-Leste by country
Source: SEAR AERF 2016
90%
Thailand*
Timor-Leste
Control of Hepatitis B is accelerated
Figure 7: HepB vaccine and HepB3 coverage, 2016
Figure 8: HepB vaccine use
HepB3 coverage
Country
2012
2013
2014
2015
2016
Bangladesh
94
96
97
97
97
Bhutan
97
97
99
99
98
DPR Korea
96
93
93
96
96
DTP-Hib-HepB (Pentavalent)
India
73
70
79
87
88
DTP-HepB Tetra/Mono HepB
Indonesia
83
85
78
78
79
Maldives
99
99
99
99
99
Myanmar
58
75
88
89
90
Nepal
90
92
92
91
87
Sri Lanka
99
99
99
99
99
Thailand
98
99
99
99
99
Timor-Leste
83
82
77
76
85
SEAR
77
76
82
87
88
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
Maternal and neonatal tetanus elimination is sustained
Figure 9: TT2+ coverage by country, 2012-2016
Figure 10: MNT elimination status
100
80
Eliminated from 2000 – May 2016
2012
60
2013
40
2014
Eliminated before 2000
2015
20
Timor-Leste
Thailand
Sri Lanka
Nepal
Myanmar
Maldives
Indonesia
India
DPR Korea
Bhutan
Bangladesh
2016
0
Source: WHO/UNICEF JRF, Country oicial esimates, 2012-2016
13
Polio-free status is maintained
Table 7: NID/SNID and date of last WPV confirmed cases, 1995-2016 by country
Country
Year of 1st NID
Total NID rounds
Last NID round
SNIDs in 2016
Last WPV conirmed case
Bangladesh
1995
40
Dec-13
Yes
22-Nov-06
Bhutan
1995
2
Nov-95
No
1986*
DPR Korea
1997
12
Nov-02
No
1996
India
1995
41
Feb-16
Yes
13-Jan-11
Indonesia
1995
14
Mar-16
Yes
20-Feb-06
Maldives
1996
8
Jan-01
No
1994
Myanmar
1996
23
Feb-16
Yes
28-May-07
Nepal
1996
27
Jan-14
Yes
30-Aug-10
Sri Lanka
1995
8
Dec-00
No
Nov-93
Thailand
1994
10
Jan-00
No
Apr-97
Timor-Leste
1995**
11
Aug-15
No
1995
* Clinically conirmed polio
** SIA conducted with Indonesia.
Figure 11: Last WPV confirmed cases by type in SEAR
Table 8: Environmental surveillance for poliovirus detection, 2014-2016
WPV type 2, U�ar Pradesh,
India, 1999
# VDPVs
detected
Number
of samples
collected
# WPVs
detected
# VDPVs
detected
Number
of samples
collected
# WPVs
detected
# VDPVs
detected
2016
# WPVs
detected
WPV type 3, Jharkhand,
India, 2010
2015
Number
of samples
collected
2014
Bangladesh
-
-
-
11
0
0
78
0
0
India
947
0
12
942
0
11
1,159
0
6
Indonesia
-
-
-
-
-
-
6
0
0
Thailand
-
-
-
-
-
-
8
0
0
SEAR
947
0
12
953
0
11
1,251
0
6
Country
WPV type 1, West Bengal,
India, 2011
Note: Environmental surveillance started- Bangladesh in 2015, India in 2001, Indonesia and Thailand in 2016
14
Table 9: AFP surveillance indicators by country, 2014-2016
2014
Country
AFP
cases
WPV
conirmed
cases
VDPV
cases
Bangladesh
1,478
0
0
2.74
Bhutan
11
0
0
DPR Korea
115
0
India
54,101
0
Indonesia
1,765
0
0
2015
AFP
WPV
conirmed
cases
VDPV
cases
98
1,413
0
0
2.78
4.84
73
9
0
0
0
2.00
100
99
0
31
12.37
87
46,978
0
2.43
89
1,428
0
0
NonAdequate stool
polio
specimen collec�on
AFP ratea
percentageb
2016
AFP
WPV
conirmed
cases
VDPV
cases
97
1,437
0
0
2.85
99
4.18
67
11
0
0
5.11
73
0
1.72
100
105
0
0
1.83
98
22
10.78
86
46,533
0
13
10.57
87
2.04
92
1,398
0
0
1.89
87
NonAdequate stool
polio
specimen collec�on
AFP ratea
percentageb
NonAdequate stool
polio
specimen collec�on
AFP ratea
percentageb
Maldives
1
0
0
1.12
100
5
0
0
5.60
60
2
0
0
2.11
0
Myanmar
389
0
0
1.82
96
336
0
2
2.34
93
466
0
0
3.38
96
Nepal
486
0
0
4.85
95
394
0
0
3.87
94
455
0
0
5.15
96
Sri Lanka
84
0
0
1.59
75
70
0
0
1.35
77
65
0
0
1.20
85
Thailand
238
0
0
1.97
79
183
0
0
1.36
65
246
0
0
1.95
75
Timor-Leste
3
0
0
0.59
67
0
0
0
0.00
0
10
0
0
1.87
50
SEAR
58,671
0
3
9.45
87
50,915
0
2
8.41
87
50,728
0
0
8.33
87
a
Number of discarded AFP cases per 100,000 children under 15 years of age.
1
Excludes twelve type 2 VDPV specimens from sewage
b
2
Percent with 2 specimens, 24 hours apart and within 14 days of paralysis onset.
Excludes eleven type 2 VDPV specimens from sewage
3
Excludes six type 2 VDPV specimens from sewage
Figure 12: AFP surveillance indicators by first administrative level1, 2016
Non-polio AFP rate*
% Adequate Stool Specimen Collection**
1
2
No non-polio AFP case
Bhutan, Maldives & Timor-Leste by Country
*Number of discarded AFP
cases per 100,000 children
under 15 years of age.
**Percentage with 2 specimens
collected at least 24 hours apart and
within 14 days of paralysis onset
15
Towards measles elimination and rubella/CRS control
Figure 13: MCV1 coverage by country, 2012-2016
Figure 14: Status of sub-national coverage for 1st dose of measles
and rubella containing vaccine in the SEA Region, 2016
100
100
90
80
2012
80
2013
40
2014
70
% of districts
60
2015
20
2016
0
Sri Lanka
Thailand
Timor-Leste
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
40
30
Figure 15: Rubella vaccine introduction through routine immunization
20
>95%
Source: WHO/UNICEF JRF , 2017
Expanded Programme on Immunization (EPI)
REGIONAL FACT SHEET 2017
WHO South-East Asia Region
Acronyms
AD
Auto disable
MCV1
First dose MCV
AEFI
Adverse events following immunization
MCV2
Second dose MCV
AFP
Acute flaccid paralysis
MICS
Multiple indicator cluster survey
BCG
Bacillus Calmette-Guérin vaccine
MMR
Measles mumps rubella vaccine
CES
Coverage evaluation survey
MNT
Maternal and neonatal tetanus
cMYP
Comprehensive multi-year plan
MR
Measles rubella vaccine
CRS
Congenital rubella syndrome
NCIP
National committee on immunization practices
DHS
Demographic health survey
NID
National immunization day
DT
Diphtheria tetanus toxoid, pediatric
NTAGI
National technical advisory group on immunization
DTP
Diphtheria – tetanus – pertussis vaccine
NT
Neonatal tetanus
DTP3
3rd dose DTP
OPV
Oral poliovirus vaccine
DTP-Hib-HepB
Pentavalent vaccine
OPV3
3rd dose OPV
DTP-Hib-HepB3
3rd dose pentavalent vaccine
bOPV
Bivalent OPV
EPI
Expanded Programme on Immunization
tOPV
Trivalent OPV
GDP
Gross domestic product
PCV
Pneumococcal conjugate vaccine
HCW
Health care worker
SEAR
WHO South-East Asia Region
HepB
Hepatitis B vaccine
SEARO
WHO South-East Asia Regional Office
HepB3
3rd dose HepB
SIA
Supplementary immunization activities
Hib
Haemophilus influenzae type B vaccine
SNID
Subnational immunization day
HPV
Human papilloma virus vaccine
Td
Tetanus diphtheria toxoid; older children, adults
IgM
Immunoglobulin M
TT
Tetanus toxoid
IPV
Inactivated poliovirus vaccine
TT2+
2 or more doses TT
JE
Japanese encephalitis
VDPV
Vaccine derived poliovirus
JE_Live-Atd
JE live attenuated vaccine
VPD
Vaccine preventable diseases
JRF
WHO UNICEF Joint Reporting Form
WCBA
Women of child bearing age
LB
Live birth
WPV
Wild poliovirus
M
Measles
Contents
Page
No.
Maternal and neonatal tetanus elimina�on is sustained
WHO South-East Asia Region
Page
No.
Regional demographic atributes
SEAR populaion density by irst administraive level
Figure 1
5
Basic informaion, 2016
Table 1
6
Page
No.
Rou�ne immuniza�on systems and services
TT2+ coverage by country, 2012-2016
Figure 9
13
MNT eliminaion status
Figure 10
13
Page
No.
Polio-free status is maintained
NID/SNID and date of last WPV conirmed cases, 1995-2016 by country
Table 7
14
Last WPV conirmed cases by type in SEAR
Figure 11
14
Table 8
14
Rouine immunizaion schedules by country, 2016
Table 2
7
Environmental surveillance for poliovirus detecion, 2014-2016
BCG, DPT3, OPV3, MCV1, MCV2, HepB 3 and RCV coverage in SEAR, 2000-2016
Figure 2
8
AFP surveillance indicators by country, 2014-2016
Table 9
15
Rouine immunizaion coverage esimates, 2012-2016
Table 3
9
AFP surveillance indicators by irst administraive level, 2016
Figure 12
15
Planning and management indicators, 2016
Table 4
10
Vaccine safety, 2016
Table 5
10
Towards measles elimina�on and rubella/congenital rubella
syndrome control
Reported vaccine preventable diseases, 2014-2016
Table 6
11
DTP3 coverage by country, 2012-2016
Figure 3
12
Districts achieving >80% DTP3 coverage by country, 2012-2016
Figure 4
DTP1-DTP3 drop-out by country, 2012-2016
DTP3 immunizaion coverage by irst administraive level, 2016
Page
No.
MCV1 coverage by country, 2012-2016
Figure 13
16
12
Status of sub-naional coverage for 1st dose of measles and
rubella containing vaccine in the SEA Region, 2016
Figure 14
16
Figure 5
12
Rubella vaccine introducion through rouine immunizaion
Figure 15
16
Figure 6
12
Suspected measles cases and outbreaks by country, 2016
Table 10
17
Measles and rubella laboratory surveillance indicators, 2016
Table 11
18
Network of WHO supported laboratories for VPD surveillance in SEAR
Figure 16
19
Page
No.
Control of Hepa��s B is accelerated
HepB3 coverage, 2012-2016
Figure 7
13
HepB vaccine use
Figure 8
13
The Immunizaion and Vaccine Development (IVD) unit of the Department of Family Health, Gender and Life Course (FGL), World Health Organizaion (WHO), Regional Oice
for South-East Asia (SEARO) has been producing annually the Expanded Programme on Immunizaion (EPI) fact sheets since 2002 for all SEA countries and the region. The
primary data source of the EPI fact sheets are the WHO-UNICEF joint reporing form (JRF) and SEARO annual EPI reporing form (AERF) in which each country oicially reports
EPI and vaccine preventable diseases (VPD) related core informaion annually. The EPI factsheets 2017 are based on 2016 data reported to WHO SEARO by the Member States.
Regional demographic attributes
Figure 1: SEAR population density by first administrative level*
*Populaion density by second administraion
level for Bhutan, Sri Lanka and Timor-Leste.
Disclaimer: The boundaries and names shown and the designaions used on all the maps do not
imply the expression of any opinion whatsoever on the part of the World Health Organizaion
concerning the legal status of any country, territory, city or area of its authoriies, or concerning the
delimitaion of its froniers or boundaries.
5
Table 1: Basic information, 2016
2016 popula�on1
Mortality2
Administra�ve levels1
Live births
Children
< 1 year
Children
< 5 years
Children
< 15 years
Neonatal
mortality rate
(per 1000 LB)
Infant
mortality rate
(per 1000 LB)
Under ive
mortality rate
(per 1000 LB)
Maternal
mortality
ra�o (per
100000 LB)
Number of
provinces /
regions /
divisions
Number
of
districts
160,707,634
3,279,741
3,138,712
15,507,183
50,339,679
23.3
30.7
37.6
176
8
64
Bhutan
757,042
12,869
11,227
82,561
229,796
18.3
27.2
32.9
148
-
20
DPR Korea
24,327,698
342,884
339,367
1,696,094
5,927,740
13.5
19.7
24.9
82
11
210
India
1,300,000,000
27,005,535
26,008,988
121,400,000
400,700,000
27.7
37.9
47.7
174
36
676
Indonesia
258,704,986
4,858,600
4,760,891
23,960,310
70,096,861
13.5
22.8
27.2
126
34
514a
Maldives
338,434
6,592
8,711
16,311
91,793
4.9
7.4
8.6
68
-
20
Myanmar
52,088,703
1,009,793
945,877
4,626,063
14,493,639
26.4
39.5
50
178
17
330b
Nepal
28,624,299
637,263
660,629
2,959,177
8,676,336
22.2
29.4
35.8
258
5
75
Sri Lanka
21,164,458
331,073
330,461
1,820,143
5,333,443
5.4
8.4
9.8
30.0
9
26
Thailand
65,931,550
704,058
627,185
3,565,020
11,433,331
6.7
10.5
12.3
20
77
928
TimorLeste
1,231,262
35,426
33,548
176,377
493,795
22.3
44.7
52.6
215
-
13
SEAR
1,913,876,066
38,223,834
36,865,596
175,809,239
567,816,413
24.3
34
42.5
164
-
-
Country
Total
popula�on
Bangladesh
Source:
1
SEAR annual EPI reporing form, 2016
2
WHO, World Health Staisics ,2016
a
District & city
6
b
Township
Routine immunization systems and services
Table 2: Routine immunization schedules by country, 2016
Country
BCG
DTP
HepB
MCV
OPV
Other vaccina�ons
TT
Vitamin A
6-59M
(not given
through EPI)
PCV- 6W, 10W, 18W
Bangladesh
At birth
DTPHibHepB - 6W, 10W, 14W
MR-38W, 15M
6W, 10W, 14W
IPV-14W
Females 15Y to 49Y (5 doses with an
interval of + 1 month, + 6 months, + 1 year
and + 1 year with preceding dose)
Bhutan
At birth
HepB- At birth
DTPHibHepB- 6W, 10W, 14W
DTP- 24M
MMR- 9M, 24M
At birth, 6W, 10W, 14W
IPV-14W
Td- 6Y, 12Y
6-30M
HPV- Girls 12Y & Grade VI students
DPR Korea
At birth
HepB- At birth
DTPHibHepB - 6W, 10W, 14W
Measles-9M,
15M
6W, 10W, 14W
IPV-14W
Td - 3M, 4M of pregnancy
6-59M
-
India
At birth
HepB - At birth
DTPHibHepB - 6W, 10W, 14W
DTP - 16-24M, 5Y
Measles-9-12M,
16-24M
MR- 9M-2Y
(Feb 2017,
subnaional)
At birth, 6W, 10W, 14W,
16-24M
IPV- 6W, 14W (as fracional
dose)
10Y and 16Y, 2 doses/booster for pregnant
women
9 months, 18
months and
6 months
interval ill
age 5 years
JE_LiveAtd - 9M and 16-24M (JE endemic
districts)
PCV - (Apr 2017, upto 1Y, subnaional)
Rotavirus-6W,10W,14W (…..2017, upto
1 year, subnaional)
Indonesia
1M
HepB- 0-7 days of birth
DTPHibHepB - 2M, 3M, 4M, 18M
Measles-9M,
24 M
1M, 2M, 3M, 4M
IPV-4M
TT- 15-39Y female
DT - 6-7Y
Td- 7-8Y , 8-9Y
6-59M
-
Maldives
At birth
HepB-At birth
DTPHibHepB - 2M, 4M, 6M
Measles-9M
MMR - 18M
2M, 4M, 6M (+15Y pilgrims)
IPV-6M
Td - Females 15Y (+1M, +6M, +1Y, +1Y)
9-59M
Men ACWY- +15Y pilgrims
YF- +15Y travelers
Myanmar
Birth to 2M
HepB- At birth
DTPHibHepB- 2M, 4M, 6M
MR- 9M
Measles- 18M
2M, 4M, 6M
IPV- 4M
First contact during pregnancy and 4 weeks
later
6-59M
-
Nepal
At birth
DTPHibHepB - 6W, 10W, 14W
MR-9M, 15M
6W, 10W, 14W
IPV-14W
Td- First contact pregnancy, +1M
6-59M, +6M
JE_LiveAtd - 12M (high-risk districts)
PCV- 6W, 10W, 9M
MMR - 9M, 3Y
2M, 4M, 6M, 18M, 5Y
IPV- 2M, 4M (as fracional
dose)
DT - 5Y
Td - 12Y (grade 7)
TT - Pregnant women (2 doses in 1st
pregnancy and 1 dose in subsequent 3
pregnancies)
6-36M
JE_LivteAtd - 1Y
Typhoid - high risk groups
At birth
DTPHibHepB - 2M, 4M, 6M
DTP - 18M
Thailand
At birth
HepB - At birth, 1M (new-born
from HepB carrier mother)
DTPHepB - 2M, 4M, 6M
DTP - 1.5Y, 4Y
Timor-Leste
At Birth
HepB- At birth (Feb 2016)
DTPHibHepBIPV- 6W, 10W, 14W
DPT-18M
Sri Lanka
Source: WHO/UNICEF JRF 2016
MMR - 9M, 2.5Y
2M, 4M, 6M, 1.5Y, 4Y
IPV-4M
Td- 12Y (grade 6), Pregnant women
1st contact, +1M, +6M (depending on
vaccinaion history)
-
JE_LiveAtd- 1.5Y, 2.5Y (29 provinces)
JE_Inactd - 1.5Y (2 doses 1M apart), 2.5Y
Rotavirus- 2m, 4M (pilot in selected
provinces)
HPV- females at grade 5 and grade 6
(pilot in selected provinces)
MR-9M, 18 M
Birth, 6W, 10W, 14W
IPV-14W
Females 15Y-49Y (1st pregnancy contact,
+1M, +6M, +1Y, +1Y)
DT- 6Y
6-36M (6M
interval)
-
W=Week
M=Month
7
Y=Year
Figure 2: BCG, DPT3, OPV3, MCV1, MCV2, HepB 3 and RCV coverage in SEAR, 2000-2016
100
80
Coverage (%)
60
40
20
Year
BCG
DPT3
OPV3
MCV1
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
8
MCV2
HepB3
RCV
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
0
Table 3: Routine immunization coverage estimates, 2012-2016
BCG
Country
DTP3
OPV3
MCV1
2012
2013
2014
2015
2016
2012
2013
2014
2015
2016
2012
2013
2014
2015
2016
2012
2013
2014
2015
2016
Bangladesh
98
99
99
99
99
94
96
97
97
97
94
96
97
97
97
88
91
94
94
94
Bhutan
95
97
99
99
99
97
97
99
99
98
97
97
98
98
97
95
94
97
97
97
DPR Korea
98
98
98
97
97
96
93
93
96
96
99
99
99
99
99
99
99
99
98
99
India
90
91
89
87
89
82
83
85
87
88
79
82
84
86
86
83
83
85
87
88
Indonesia
88
86
82
80
81
83
85
78
78
79
84
86
80
80
80
82
81
75
75
76
Maldives
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
98
99
99
99
99
Myanmar
87
86
92
94
88
84
75
88
89
90
87
76
88
89
89
84
86
88
84
91
Nepal
96
97
99
94
93
90
92
92
91
87
90
92
92
90
85
86
88
88
85
83
Sri Lanka
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
Thailand
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
98
99
99
99
99
Timor-Leste
86
86
84
84
85
83
82
77
76
85
83
82
76
75
83
73
70
74
70
78
SEAR
91
91
90
88
89
84
85
86
87
88
82
84
85
87
87
84
84
85
86
87
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
9
Most recent EPI CES
India
Updated microplans that include
ac�vi�es to improve
immuniza�on
coverage
DPR Korea
Spending on rou�ne
immuniza�on
programme by the
government
Bhutan
Table 5: Vaccine safety, 2016
Spending on vaccines
by the government
Bangladesh
NTAGI
Country
cMYP for
immuniza�on
Table 4: Planning and management indicators, 2016
27%
29%
64 districts
(100%)
EPI CES 2015
24%
20 districts
(100%)
Naional Health Survey,
2012
no data
210 districts
(100%)
CES and MICS
56%
676 districts
(100%)
Naional Family Health
Survey-4 2015
Indonesia
Yes
11,832
112
Maldives
Yes
2
0
2014-2018
fully
funcional
2014-2018
fully
funcional
41%
2016-2020
fully
funcional
no
data
2013-2017
fully
funcional
50%
Adverse events following immuniza�on (AEFI)
Country
Na�onal system
to monitor AEFI
No. AEFI
Reported
Of the total adverse
events reported no. of
serious
Bangladesh
Yes
2,563
54
Bhutan
Yes
ND
9
DPR Korea
Yes
-
-
India
Yes
1,393
1280
Indonesia
2015-2019
fully
funcional
90%
88%
ND
Basic Health Survey 2013,
District Coverage Survey
in 10 provinces and 31
districts 2015
Maldives
2016-2020
fully
funcional
100%
72%
20 atolls
(100%)
DHS ongoing
Myanmar
Yes
63
10
Myanmar
2017 -2021
fully
funcional
6%
24%
ND
Demographic and Health
Survey 2015-2016
Nepal
Yes
1,684
34
Nepal
2011-2016
fully
funcional
22%
24%
75 districts
(100%)
Demographic Health
Survey 2016
Sri Lanka1
Yes
9,389
225
Sri Lanka
2017-2021
fully
funcional
no
data
74%
26 districts
(100%)
EPI coverage survey
Nuwara Eliya district 2016
Thailand
Yes
751
0
Thailand
2012-2016
fully
funcional
no
data
no data
77 provinces
(100%)
CES for basic and schoolbased immunizaion 2013
Timor-Leste
Yes
ND
0
Timor-Leste 2016-2020
fully
funcional
39%
13 districts
(100%)
EPI CES Dili municipality
and 12 other
municipaliies 2015
Source: WHO/UNICEF JRF, 2016
76%
ND: no data
10
Source: WHO/UNICEF JRF, 2016
Adverse Events Following Immunizaion; Sri Lanka AEFI data do not relect cases
but events.
1
Table 6: Reported vaccine preventable diseases, 2014-2016
Pertussis
Total
tetanus (NT)
Measles
Rubella
Mumps
JE
Polio
Diphtheria
Pertussis
Total
tetanus (NT)
Measles
Rubella
Mumps
JE
Polio
Diphtheria
Pertussis
Total
tetanus (NT)
Measles
Rubella
Mumps
JE
2016
Diphtheria
2015
Polio
2014
Bangladesh
0
13
12
ND
289
381
ND
183
0
6
11
559
(117)
240
189
ND
76
0
2
1
441
(110)
972
165
ND
1,294
Bhutan
0
0
0
0
0
0
206
2
0
0
12
0
11
1
620
5
0
0
4
0
45
3
795
5
DPR Korea
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
India
0a 6,094 46,706
5,017
26,530
(492)
5,716
0
Indonesia
0
430
2,082
1,023
12,943
(75)
3,542
ND
72
0
252
1,004
ND
(69)
9,863
826
ND
39
0
342
Maldives
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
Myanmar
0
29
5
73
(32)
122
30
ND
50
0c
87
5
ND
(30)
6
34
ND
113
Nepal
0 1,079
6,096
ND
(57)
1,279
704
34,034 1,304 0
236
4,416
888
(266)
1,599
626
38,858
Sri Lanka
0
0
38
9 (0)
1,686
10
383
21
0
0
107
15 (0)
1,568
9
Thailand
0
19
14
81 (2)
146
152
3,704
31
0
19
51
0
154
Timor-Leste 0
2
0
0
47
1
0
0
0
1
5
0
48
Country
SEAR
a
0 7,666 54,953
Excludes 3 VPDVs (type 2)
b
1,657 0b 2,365 25,206
3,781
(227)
17,250 10,311
ND
1,627
826
33(6%)
6,962
1,238
ND
43
0
0
0
0
0
0
0
0
136
2
194
(21)
266
10
ND
393
937
0
140
4,890
766 (7)
1,269
656
30,610
98
ND
17
0
0
54
5(0)
112
0
311
18
240
3,121
23
0
16
84
61 (0)
652
7
23
21
5
ND
0
0
0
6
0
2
8
0
1
2,268
30,168 5,850
(491)
ND
1,620 0d 3,380 37,274
6,126
3,730
43,045 10,536 38,327 3,320 0 2,966 30,817
43,657 7,783 42,599 2,830 0 4,016 43,141
(658)
(933)
Excludes 2 VDPVs (type 2)
c
Excludes 2 cVDPVs (type 2)
d
Excludes 1 VDPV (Type 2)
Source: WHO/UNICEF JRF (2014-2016)
ND=No data
11
5,250
(366)
27,530 12,398 31,739 3,500
Figure 4: Districts achieving >80% DTP3 coverage
Figure 3: DTP3 coverage by country, 2012-2016
by country, 2012-2016
100
100
80
2012
80
2012
2013
60
60
2013
2014
40
2014
2015
40
2015
2016
20
20
2016
0
0
Bangladesh
Bangladesh
Bhutan
DPR Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Bhutan
DPR Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Timor-Leste
Source: WHO/UNICEF JRF , 2017
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
Figure 5: DTP1-DTP3 drop-out by country, 2012-2016
* data from province level
Figure 6: DTP3 immunization coverage by
first administrative level*, 2016
20
15
2012
2013
10
2014
2015
5
Timor-Leste
Thailand
Sri Lanka
Nepal
Myanmar
Maldives
Indonesia
India
DPR Korea
Bhutan
0
Bangladesh
2016
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
*Thailand, Bhutan, Maldives & Timor-Leste by country
Source: SEAR AERF 2016
90%
Thailand*
Timor-Leste
Control of Hepatitis B is accelerated
Figure 7: HepB vaccine and HepB3 coverage, 2016
Figure 8: HepB vaccine use
HepB3 coverage
Country
2012
2013
2014
2015
2016
Bangladesh
94
96
97
97
97
Bhutan
97
97
99
99
98
DPR Korea
96
93
93
96
96
DTP-Hib-HepB (Pentavalent)
India
73
70
79
87
88
DTP-HepB Tetra/Mono HepB
Indonesia
83
85
78
78
79
Maldives
99
99
99
99
99
Myanmar
58
75
88
89
90
Nepal
90
92
92
91
87
Sri Lanka
99
99
99
99
99
Thailand
98
99
99
99
99
Timor-Leste
83
82
77
76
85
SEAR
77
76
82
87
88
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
Maternal and neonatal tetanus elimination is sustained
Figure 9: TT2+ coverage by country, 2012-2016
Figure 10: MNT elimination status
100
80
Eliminated from 2000 – May 2016
2012
60
2013
40
2014
Eliminated before 2000
2015
20
Timor-Leste
Thailand
Sri Lanka
Nepal
Myanmar
Maldives
Indonesia
India
DPR Korea
Bhutan
Bangladesh
2016
0
Source: WHO/UNICEF JRF, Country oicial esimates, 2012-2016
13
Polio-free status is maintained
Table 7: NID/SNID and date of last WPV confirmed cases, 1995-2016 by country
Country
Year of 1st NID
Total NID rounds
Last NID round
SNIDs in 2016
Last WPV conirmed case
Bangladesh
1995
40
Dec-13
Yes
22-Nov-06
Bhutan
1995
2
Nov-95
No
1986*
DPR Korea
1997
12
Nov-02
No
1996
India
1995
41
Feb-16
Yes
13-Jan-11
Indonesia
1995
14
Mar-16
Yes
20-Feb-06
Maldives
1996
8
Jan-01
No
1994
Myanmar
1996
23
Feb-16
Yes
28-May-07
Nepal
1996
27
Jan-14
Yes
30-Aug-10
Sri Lanka
1995
8
Dec-00
No
Nov-93
Thailand
1994
10
Jan-00
No
Apr-97
Timor-Leste
1995**
11
Aug-15
No
1995
* Clinically conirmed polio
** SIA conducted with Indonesia.
Figure 11: Last WPV confirmed cases by type in SEAR
Table 8: Environmental surveillance for poliovirus detection, 2014-2016
WPV type 2, U�ar Pradesh,
India, 1999
# VDPVs
detected
Number
of samples
collected
# WPVs
detected
# VDPVs
detected
Number
of samples
collected
# WPVs
detected
# VDPVs
detected
2016
# WPVs
detected
WPV type 3, Jharkhand,
India, 2010
2015
Number
of samples
collected
2014
Bangladesh
-
-
-
11
0
0
78
0
0
India
947
0
12
942
0
11
1,159
0
6
Indonesia
-
-
-
-
-
-
6
0
0
Thailand
-
-
-
-
-
-
8
0
0
SEAR
947
0
12
953
0
11
1,251
0
6
Country
WPV type 1, West Bengal,
India, 2011
Note: Environmental surveillance started- Bangladesh in 2015, India in 2001, Indonesia and Thailand in 2016
14
Table 9: AFP surveillance indicators by country, 2014-2016
2014
Country
AFP
cases
WPV
conirmed
cases
VDPV
cases
Bangladesh
1,478
0
0
2.74
Bhutan
11
0
0
DPR Korea
115
0
India
54,101
0
Indonesia
1,765
0
0
2015
AFP
WPV
conirmed
cases
VDPV
cases
98
1,413
0
0
2.78
4.84
73
9
0
0
0
2.00
100
99
0
31
12.37
87
46,978
0
2.43
89
1,428
0
0
NonAdequate stool
polio
specimen collec�on
AFP ratea
percentageb
2016
AFP
WPV
conirmed
cases
VDPV
cases
97
1,437
0
0
2.85
99
4.18
67
11
0
0
5.11
73
0
1.72
100
105
0
0
1.83
98
22
10.78
86
46,533
0
13
10.57
87
2.04
92
1,398
0
0
1.89
87
NonAdequate stool
polio
specimen collec�on
AFP ratea
percentageb
NonAdequate stool
polio
specimen collec�on
AFP ratea
percentageb
Maldives
1
0
0
1.12
100
5
0
0
5.60
60
2
0
0
2.11
0
Myanmar
389
0
0
1.82
96
336
0
2
2.34
93
466
0
0
3.38
96
Nepal
486
0
0
4.85
95
394
0
0
3.87
94
455
0
0
5.15
96
Sri Lanka
84
0
0
1.59
75
70
0
0
1.35
77
65
0
0
1.20
85
Thailand
238
0
0
1.97
79
183
0
0
1.36
65
246
0
0
1.95
75
Timor-Leste
3
0
0
0.59
67
0
0
0
0.00
0
10
0
0
1.87
50
SEAR
58,671
0
3
9.45
87
50,915
0
2
8.41
87
50,728
0
0
8.33
87
a
Number of discarded AFP cases per 100,000 children under 15 years of age.
1
Excludes twelve type 2 VDPV specimens from sewage
b
2
Percent with 2 specimens, 24 hours apart and within 14 days of paralysis onset.
Excludes eleven type 2 VDPV specimens from sewage
3
Excludes six type 2 VDPV specimens from sewage
Figure 12: AFP surveillance indicators by first administrative level1, 2016
Non-polio AFP rate*
% Adequate Stool Specimen Collection**
1
2
No non-polio AFP case
Bhutan, Maldives & Timor-Leste by Country
*Number of discarded AFP
cases per 100,000 children
under 15 years of age.
**Percentage with 2 specimens
collected at least 24 hours apart and
within 14 days of paralysis onset
15
Towards measles elimination and rubella/CRS control
Figure 13: MCV1 coverage by country, 2012-2016
Figure 14: Status of sub-national coverage for 1st dose of measles
and rubella containing vaccine in the SEA Region, 2016
100
100
90
80
2012
80
2013
40
2014
70
% of districts
60
2015
20
2016
0
Sri Lanka
Thailand
Timor-Leste
Source: WHO/UNICEF esimates of naional immunizaion coverage, July 2017 revision
40
30
Figure 15: Rubella vaccine introduction through routine immunization
20
>95%
Source: WHO/UNICEF JRF , 2017